ArticleMolecules (Basel, Switzerland)2021
Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells.Frontiers in pharmacology · 2023Pooled it
- Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.Molecules (Basel, Switzerland) · 2022Pooled it
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Trial
- Luteolin as a Cancer Therapeutic: From Preclinical Evidence to Translational Potential.Chemistry & biodiversity · 2026Review
- TrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance.Drug development research · 2026Review
- Network pharmacology and bioinformatics analysis-based strategy for exploring the mechanisms of luteolin in the treatment of five types of cancer: A retrospective computational study.The Journal of international medical research · 2026Article
- The Role and Mechanism of Nrf2 in Ameliorating Oxidative Stress and Inflammation in IR Mice by Aerobic Exercise.International journal of molecular sciences · 2026Article
- Enhanced antitumor activity of atorvastatin and luteolin, with or without doxorubicin, in a solid Ehrlich carcinoma mouse model: modulation of ABC transporters, telomerase, and cancer stem cells.Medical oncology (Northwood, London, England) · 2026Article
- Screening the Active Phytochemicals FromCancer innovation · 2025Review
- Potential of Apigenin, Berberine, Chrysin, and Luteolin to Overcome Doxorubicin Resistance in Acute Promyelocytic Leukemia HL-60 Cells.International journal of molecular sciences · 2025Article
- Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.Cancer pathogenesis and therapy · 2025Review
- Linolenic Acid Inhibits Cancer Stemness and Induces Apoptosis by Regulating Nrf2 Expression in Gastric Cancer Cells.Current issues in molecular biology · 2025Article
- Luteolin ameliorates ischemic/reperfusion injury by inhibiting ferroptosis.Metabolic brain disease · 2025Article
- Molecular Mechanisms of Dietary Compounds in Cancer Stem Cells from Solid Tumors: Insights into Colorectal, Breast, and Prostate Cancer.International journal of molecular sciences · 2025Review
- Targeted Therapy of Tumors and Cancer Stem Cells based on Oxidant-regulated Redox Pathway and its Mechanism.Current computer-aided drug design · 2025Review
- Exploring the Mechanism of Lianqiao Jinbei Decoction Inhibiting HER2-Positive Breast Cancer Based on Network Pharmacology and Experimental Verification.Breast cancer (Dove Medical Press) · 2025Article
- Durian and Sapodilla Extracts Enhance Chemotherapy Sensitivity and Promote Apoptosis in Triple Negative Breast Cancer Model in Vitro: Systematic Review.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025Review
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Luteolin induces oxidative stress and apoptosis via dysregulating the cytoprotective Nrf2-Keap1-Cul3 redox signaling in metastatic castration-resistant prostate cancer cells.Molecular biology reports · 2024Article
- Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer stem cells (CSCs) are subpopulations of tumor masses with unique abilities in self-renewal, stemness maintenance, drug resistance, and the promotion of cancer recurrence. Recent studies have suggested that breast CSCs play essential roles in chemoresistance. Therefore, new agents that selectively target such cells are urgently required. Reactive oxygen species (ROS)-producing enzymes are the reason for an elevated tumor oxidant status. The nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcriptional factor, which upon detecting cellular oxidative stress, binds to the promoter region of antioxidant genes. By triggering a cytoprotective response, Nrf2 maintains cellular redox status. Cripto-1 participates in the self-renewal of CSCs. Herein, luteolin, a flavonoid found in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.